CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Daré Bioscience, Inc. - DARE CFD

3.1818
0.32%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0264
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024346 %
Charges from full value of position ($-4.63)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002124 %
Charges from full value of position ($0.40)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 3.1718
Open 3.1818
1-Year Change 813.79%
Day's Range 3.1718 - 3.1818
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 17, 2024 3.1718 0.0000 0.00% 3.1718 3.1818 3.1618
Dec 16, 2024 3.1718 0.0000 0.00% 3.1718 3.1818 3.1718
Dec 13, 2024 3.1718 0.0000 0.00% 3.1718 3.1818 3.1718
Dec 12, 2024 3.1818 -0.2100 -6.19% 3.3918 3.3918 3.1718
Dec 11, 2024 3.4718 0.1000 2.97% 3.3718 3.7318 3.2118
Dec 10, 2024 3.3218 0.1200 3.75% 3.2018 3.3518 3.2018
Dec 9, 2024 3.2318 0.0400 1.25% 3.1918 3.3118 3.1718
Dec 6, 2024 3.2118 0.0200 0.63% 3.1918 3.2218 3.1718
Dec 5, 2024 3.1918 -0.0400 -1.24% 3.2318 3.2518 3.1718
Dec 4, 2024 3.2118 -0.0300 -0.93% 3.2418 3.2518 3.1718
Dec 3, 2024 3.2118 -0.0600 -1.83% 3.2718 3.4318 3.1718
Dec 2, 2024 3.2918 -0.1200 -3.52% 3.4118 3.4218 3.2818
Nov 29, 2024 3.4018 0.1100 3.34% 3.2918 3.4018 3.2718
Nov 27, 2024 3.2918 0.1200 3.78% 3.1718 3.3318 3.1718
Nov 26, 2024 3.1718 0.0000 0.00% 3.1718 3.1818 3.1718
Nov 25, 2024 3.1718 -0.1200 -3.65% 3.2918 3.3018 3.1618
Nov 22, 2024 3.3318 0.1500 4.71% 3.1818 3.3718 3.1718
Nov 21, 2024 3.1818 0.0100 0.32% 3.1718 3.2918 3.1618
Nov 20, 2024 3.1718 0.0000 0.00% 3.1718 3.1718 3.1618
Nov 19, 2024 3.1718 0.0000 0.00% 3.1718 3.2118 3.1618

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Daré Bioscience, Inc. Company profile

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women''s health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company''s Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.
Industry: Biotechnology & Medical Research (NEC)

3655 Nobel Dr Ste 260
SAN DIEGO
CALIFORNIA 92122-1050
US

People also watch

ETH/USD

3,869.41 Price
-1.670% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

BTC/USD

104,210.30 Price
-2.280% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Gold

2,636.12 Price
-0.410% 1D Chg, %
Long position overnight fee -0.0083%
Short position overnight fee 0.0001%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

21,988.50 Price
+0.050% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0021%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading